Literature DB >> 2361736

Ocular inflammatory effects of intravitreally injected tumor necrosis factor-alpha and endotoxin.

L N Fleisher1, J B Ferrell, M C McGahan.   

Abstract

Intravitreal injection of human recombinant tumor necrosis factor-alpha (TNF) induced inflammation in the rabbit eye characterized by dilation of blood vessels in the iris, disruption of the blood-ocular barriers, infiltration of inflammatory cells into the anterior chamber, and accumulation of prostaglandin E in intraocular fluids. Inflammation first appeared on day 1, increased on day 2, and remained elevated on day 7. The inflammatory cell infiltrate in the anterior segment of the eye was largely monocytic on days 1 and 2; by day 7 large numbers of lymphocytes were also present. TNF-induced ocular inflammation therefore differed from that reported for intravitreally injected endotoxin in terms of time course and the types of inflammatory cells in the aqueous humor. In a series of experiments in which combinations of TNF and endotoxin were used, intravitreal injection of TNF, 24 h after a low dose of Escherichia coli endotoxin, produced no more inflammation than that produced by TNF following an injection of endotoxin vehicle. However, if TNF was injected 24 h before endotoxin, the resulting inflammation was greater than that observed in animals given TNF followed by endotoxin vehicle.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2361736     DOI: 10.1007/bf00915816

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  29 in total

Review 1.  Cachectin: more than a tumor necrosis factor.

Authors:  B Beutler; A Cerami
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

2.  A platelet-activating factor antagonist inhibits interleukin 1-induced inflammation.

Authors:  R M Rubin; J T Rosenbaum
Journal:  Biochem Biophys Res Commun       Date:  1988-07-15       Impact factor: 3.575

3.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

4.  Time course for prostaglandin synthesis by rabbit lens during endotoxin-induced ocular inflammation.

Authors:  L N Fleisher; M C McGahan
Journal:  Curr Eye Res       Date:  1986-09       Impact factor: 2.424

5.  Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor.

Authors:  J R Gamble; J M Harlan; S J Klebanoff; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

6.  Complement and polymorphonuclear leukocytes do not determine the vascular permeability induced by intraocular LPS.

Authors:  E L Howes; K L Wong; K T Hartiala; R O Webster; J T Rosenbaum
Journal:  Am J Pathol       Date:  1985-01       Impact factor: 4.307

7.  Antioxidant activity of aqueous and vitreous humor from the inflamed rabbit eye.

Authors:  M C McGahan; L N Fleisher
Journal:  Curr Eye Res       Date:  1986-09       Impact factor: 2.424

8.  Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor.

Authors:  G Camussi; F Bussolino; G Salvidio; C Baglioni
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

9.  Bacterial lipopolysaccharides prime macrophages for enhanced release of arachidonic acid metabolites.

Authors:  A A Aderem; D S Cohen; S D Wright; Z A Cohn
Journal:  J Exp Med       Date:  1986-07-01       Impact factor: 14.307

10.  Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.

Authors:  J M Dayer; B Beutler; A Cerami
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  13 in total

1.  Determination of a No Observable Effect Level for Endotoxin Following a Single Intravitreal Administration to Cynomolgus Monkeys.

Authors:  Vladimir Bantseev; Paul E Miller; T Michael Nork; Carol A Rasmussen; Aija McKenzie; Brian J Christian; Helen Booler; Evan A Thackaberry
Journal:  J Ocul Pharmacol Ther       Date:  2019-04-09       Impact factor: 2.671

2.  Infliximab exerts a dose-dependent effect on retinal safety in the albino rabbit.

Authors:  Shiri Zayit-Soudry; Igor Vainer; Esther Zemel; Michael Mimouni; Melvin Rabena; Dante J Pieramici; Ido Perlman; Anat Loewenstein
Journal:  Doc Ophthalmol       Date:  2017-08-19       Impact factor: 2.379

3.  Adalimumab in the therapy of uveitis in childhood.

Authors:  Sabine Biester; Christoph Deuter; Hartmut Michels; Renate Haefner; Jasmin Kuemmerle-Deschner; Deshka Doycheva; Manfred Zierhut
Journal:  Br J Ophthalmol       Date:  2006-10-11       Impact factor: 4.638

Review 4.  The pathogenesis and clinical presentation of macular edema in inflammatory diseases.

Authors:  Y Guex-Crosier
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

5.  Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets' Disease-Associated Uveitis: A Systematic Review and Meta-Analysis.

Authors:  Yunwei Hu; Zhaohao Huang; Shizhao Yang; Xiaoqing Chen; Wenru Su; Dan Liang
Journal:  Front Pharmacol       Date:  2020-06-24       Impact factor: 5.810

Review 6.  Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis.

Authors:  William D Renton; Jennifer Jung; Alan G Palestine
Journal:  Cochrane Database Syst Rev       Date:  2022-10-14

7.  Cellular response to intravitreal injection of endotoxin and xanthine oxidase in rabbits.

Authors:  M C McGahan; L N Fleisher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

8.  Adalimumab (humira™) in ophthalmology: a review of the literature.

Authors:  Piergiorgio Neri; Marta Lettieri; Cinzia Fortuna; Manuela Zucchi; Mara Manoni; Silvia Celani; Alfonso Giovannini
Journal:  Middle East Afr J Ophthalmol       Date:  2010-10

9.  Mediators of the ocular inflammatory response to interleukin-1 beta plus tumor necrosis factor-alpha.

Authors:  L Fleisher; J Ferrell; C McGahan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-02       Impact factor: 3.117

10.  Novel production of interleukin-1 receptor antagonist peptides in normal human cornea.

Authors:  M C Kennedy; J T Rosenbaum; J Brown; S R Planck; X Huang; C A Armstrong; J C Ansel
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.